Cargando…

Role of immunotherapy in localized muscle invasive urothelial cancer

The standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy or trimodality therapy with chemoradiation in select patients. Pathologic complete response (pCR) to neoadjuvant chemotherapy is a reliable predi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaur, Jasmeet, Choi, Woonyoung, Geynisman, Daniel M., Plimack, Elizabeth R., Ghatalia, Pooja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461126/ https://www.ncbi.nlm.nih.gov/pubmed/34567274 http://dx.doi.org/10.1177/17588359211045858

Ejemplares similares

Role of perioperative immunotherapy in localized renal cell carcinoma
por: Kaur, Jasmeet, et al.
Publicado: (2023)

Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
por: Ghatalia, Pooja, et al.
Publicado: (2018)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
por: Renner, Alex, et al.
Publicado: (2021)

The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013–2016 from the ClinicalTrials.gov Website
por: Ghatalia, Pooja, et al.
Publicado: (2017)

Tumor heterogeneity in muscle-invasive bladder cancer
por: Kang, Ho Won, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
por: Galsky, Matthew D, et al.
Publicado: (2021)

Editorial: Recent Advances in Diagnosis and Management of Urothelial Carcinoma
por: Ku, Ja Hyeon, et al.
Publicado: (2021)

Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma
por: Geynisman, Daniel M., et al.
Publicado: (2015)

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
por: Bilusic, Marijo, et al.
Publicado: (2022)

Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms
por: Kaur, Jasmeet, et al.
Publicado: (2023)

Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery
por: Abufaraj, Mohammad, et al.
Publicado: (2016)

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD‐1/PDL‐1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer
por: Winer, Arthur, et al.
Publicado: (2019)

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
por: Jang, H. Josh, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
por: Peyrottes, Arthur, et al.
Publicado: (2021)

Current Status and Future Direction to Address Disparities in Diversity, Equity, and Inclusion in Prostate Cancer Care
por: Fu, Jerry, et al.
Publicado: (2023)

Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer
por: Miura, Yuki, et al.
Publicado: (2021)

Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma
por: Ghatalia, Pooja, et al.
Publicado: (2019)

Correction to: Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma
por: Ghatalia, Pooja, et al.
Publicado: (2019)

Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans
por: Tsamouri, Maria Malvina, et al.
Publicado: (2021)

Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer
por: Abbosh, Philip H., et al.
Publicado: (2018)

Immune escape mechanisms and immunotherapy of urothelial bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021)

Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma
por: Yassaie, Omid, et al.
Publicado: (2021)

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
por: Bevers, R F M, et al.
Publicado: (2004)

Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
por: Gupta, Shilpa, et al.
Publicado: (2017)

Perioperative immunotherapy in muscle-invasive bladder cancer
por: Lee, Hyung Ho, et al.
Publicado: (2020)

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
por: Kitamura, Hiroshi, et al.
Publicado: (2011)

Perioperative immunotherapy for muscle-invasive bladder cancer
por: Kim, In-Ho, et al.
Publicado: (2020)

Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
por: Kim, Tae Jin, et al.
Publicado: (2020)

Immunotherapy in urothelial carcinoma: fade or future standard?
por: Breyer, Johannes, et al.
Publicado: (2016)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab
por: Chiang, Ryan S, et al.
Publicado: (2022)

Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer
por: Suh, Jungyo, et al.
Publicado: (2020)

Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer
por: Ochoa, Andrea E., et al.
Publicado: (2016)

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
por: Zichi, Clizia, et al.
Publicado: (2017)

The urothelial cell line UROtsa transformed by arsenite and cadmium display basal characteristics associated with muscle invasive urothelial cancers
por: Hoggarth, Zachary E., et al.
Publicado: (2018)

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
por: Dietrich, Brian, et al.
Publicado: (2018)

Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs
por: Yang, Huang-Yu, et al.
Publicado: (2019)

Between the Hammer and Anvil: Resolution of unresectable muscle invasive bladder cancer in a renal transplant patient after cessation of immunosuppressive therapy
por: Strauss, David, et al.
Publicado: (2023)

Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma
por: Sanford, Thomas, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8vkkrfnus6v7fftdjocmfil6d3